|
|
4 Cromwell
Irvine, CA 92618 USA
phone:
888-424-6527
fax:
949-366-3325 |
| Symbol |
BLTI |
| Exchange |
Nasdaq |
| Founded |
1986 |
| Employees |
156 |
|
|
www.biolase.com |
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Dental, cosmetic and surgical laser products. |
 |
| Management |
| Jeffrey W Jones, Pres., CEO and CTO; Richard Harrison, CFO; Douglas Downing, VP of Operations; Keith Bateman, EVP of Global Sales and Marketing |
|
|
|
|
| Keywords |
| dental, dental laser, oral surgery, orthodontics, hard tissue, bone teeth, soft tissue, gums, biomaterials, hydrokinetic |
|
|
|
|
Description |
| BioLase Technology manufactures and markets dental laser systems that allow dentists, oral surgeons and other specialists to perform common dental procedures, including cosmetic applications. |
 |
| Products / Services |
BioLase's principal product, the Waterlase system, is used for hard and soft tissue dental procedures, and can be used to perform procedures performed using dental drills, scalpels and other dental instruments.
The company's LaserSmile system is used for soft tissue procedures and tooth whitening. The company's Diolase, Diolase Plus and Pulsemaster systems are used for soft tissue procedures. Accessories and disposables include handpieces, laser tips, and tooth whitening gel.
|
 |
| Market / Customers |
BioLase markets its laser systems in the US, Canada, Australia and various countries around Europe and the Pacific Rim. It sells products domestically to customers through a direct sales force.
|
 |
| Competitors / Substitutes / Alternatives |
American Medical Technologies Inc., BriteSmile Inc., Valley Forge Scientific Corp.
|
 |
| Strategy |
The company has signed an exclusive multi-year agreement with Henry Schein Inc. to distribute Biolase's professional dental laser system products in North America. Under the agreement, Henry Schein is the exclusive distributor of Biolase's line of dental laser systems. Henry Schein will pay Biolase a $5 million license fee for access to the company's portfolio of intellectual property and technology, and Henry Schein must meet certain performance criteria includign minimum purchase commitments to maintain its exclusivity.
|
 |
|
|
| |
|
|
|
|